Cardiovascular Health

An oral dose of 0.6 mg per 5 mL of colchicine could aid individuals who have trouble with swallowing pills.

Traditional risk factors were more contributable to cryptogenic ischemic stroke (CIS) without patent foramen ovale (PFO), whereas nontraditional ones were more critical for CIS with PFO.

Promoting weight management prior to pregnancy and in early life may yield stronger cardiovascular and maternal health.

Small changes in blood pressure and pulse were shown in patients of all ages, and the authors suggested that these are monitored carefully in patients being treated for ADHD.

The registry data showed that cardiac magnetic resonance (CMR) was obtained in more clinically complex patients with recurrent pericarditis.

Patients in the treatment group had a 21% lower risk of cardiovascular death or first heart failure hospitalization overall, but the between-group difference did not meet the threshold for statistical significance for this primary end point.

The trial is the first to test the cardiovascular benefits of an oral glucagon-like peptide-1 (GLP-1) agonist.

Christian Ruff, MD, highlights abelacimab’s potential to significantly reduce bleeding in patients with high-risk atrial fibrillation.

The DapaTAVI study is the first trial of a sodium-glucose cotransporter-2 (SGLT2) inhibitor for valvular disease.

Rivaroxaban offers more predictable dosing, eliminates frequent blood tests, and is less likely to interact with foods.

The results should lead to a guideline update recommending extended treatment with a reduced-dose anticoagulant in this patient population.

The STRIDE trial was first of its kind to evaluate the use of a GLP-1 agonist in PAD management.

Marc Bonaca, MD, PHH, FACC discussed semaglutide’s potential benefits for non-diabetic patients with peripheral artery disease.

Pharmacy Times will be on-site in Chicago, Illinois from March 29 through 31.

If approved, this novel monoclonal antibody therapy could become a standard of care emergency option for patients with acute myocardial infarction, which affects millions in the United States and across the world.

This new podcast will explore the latest evidence, practices, and innovations in the world of cardiovascular care from a pharmacist's point of view.

The innovative neonatal cardiac progenitor cell therapy is designed to repair heart tissue in patients with heart failure with preserved ejection fraction (HFpEF).

This subset of heart failure requires unique therapeutic considerations.

Vutrisiran becomes the first and only therapeutic FDA-approved to treat cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults.

Factor XI inhibitors show promise as a safer alternative to direct oral anticoagulants for preventing and treating thrombosis, offering similar efficacy with reduced bleeding risk.

The treatment is indicated for patients aged 6 and older with hypertension, the reduction of stroke in hypertension and left ventricular hypertrophy, and diabetic nephropathy in certain patients with type 2 diabetes.

The new indication would include adults with heart failure with a left ventricular ejection fraction (LVEF) of 40% or higher, such as mildly reduced or preserved LVEF.

This study found no significant difference in the sustained return of spontaneous circulation or survival to hospital discharge based on the timing of the first epinephrine administration in these patients.

Although improvements were observed in blood pressure (BP) medication adherence, there were no improvements in stain or glucose-lowering medication use.

If approved, vutrisiran would be the first FDA-approved therapy to treat both the polyneuropathy and cardiomyopathy aspects of transthyretin amyloidosis (ATTR).

Pharmacists also educate, advocate, and ensure patients with heart failure with reduced ejection fraction (HFrEF) and anemia are receiving the appropriate regimens.

In a clinical trial, tenecteplase was shown to be a comparable alternative to alteplase.

The feature is expected to be available to US users in late March 2025.

Levonorgestrel-releasing intrauterine devices were not found to increase women’s risks of these conditions.

Educating patients about lifestyle modifications is a critical part of preventing cerebrovascular events.